Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM.

Am J Kidney Dis. 2011 Mar;57(3):415-21. doi: 10.1053/j.ajkd.2010.08.037. Epub 2010 Dec 4.

PMID:
21131115
2.

The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.

Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group.

Am J Kidney Dis. 2005 Nov;46(5):925-32.

PMID:
16253734
3.

Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Kumar N, Lindberg J, David K, Morris J, Menoyo J.

Am J Nephrol. 2009;29(2):71-8. doi: 10.1159/000151275. Epub 2008 Aug 8.

PMID:
18689981
4.
5.

Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.

Panawong W, Chaiyakum A, Pongskul C.

J Med Assoc Thai. 2011 Oct;94(10):1175-83.

PMID:
22145501
6.

Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?

Tentori F, Hunt WC, Rohrscheib M, Zhu M, Stidley CA, Servilla K, Miskulin D, Meyer KB, Bedrick EJ, Johnson HK, Zager PG.

J Am Soc Nephrol. 2007 Aug;18(8):2377-84. Epub 2007 Jul 18.

7.
8.

K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?

Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG.

Int Urol Nephrol. 2006;38(3-4):739-43. Epub 2006 Dec 11.

PMID:
17160632
9.

Do differences in dialysis prescription impact on KDOQI bone mineral targets? The Pan Thames Renal Audit.

Davenport A, Gardner C, Delaney M; Pan Thames Renal Audit Group.

Blood Purif. 2010;30(2):111-7. doi: 10.1159/000319954. Epub 2010 Aug 12.

PMID:
20714141
10.

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC; ARO Investigators.

Nephrol Dial Transplant. 2011 Jun;26(6):1948-55. doi: 10.1093/ndt/gfq219. Epub 2010 Apr 25.

11.

Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

Wagner M, Ansell D, Kent DM, Griffith JL, Naimark D, Wanner C, Tangri N.

Am J Kidney Dis. 2011 Jun;57(6):894-902. doi: 10.1053/j.ajkd.2010.12.023. Epub 2011 Apr 12.

12.

Consistent control of mineral and bone disorder in incident hemodialysis patients.

Danese MD, Belozeroff V, Smirnakis K, Rothman KJ.

Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9. doi: 10.2215/CJN.01060308. Epub 2008 Jul 2.

13.

Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?

Morton AR, Murphy S, Hirsch D, Leblanc M, Barré P, Lok C, Hercz G, Hodsman A, Reslerova M, Levin A.

Hemodial Int. 2010 Apr;14(2):200-10. doi: 10.1111/j.1542-4758.2009.00426.x. Epub 2010 Mar 12.

PMID:
20337745
14.

Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.

Shastri J, Tran A, Covit A, Pepe J, Sherman RA.

J Ren Nutr. 2008 Jul;18(4):370-4. doi: 10.1053/j.jrn.2008.04.011.

PMID:
18558302
15.

Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan.

Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y; Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan.

Ther Apher Dial. 2008 Feb;12(1):49-54. doi: 10.1111/j.1744-9987.2007.00540.x.

PMID:
18257812
16.

Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines.

Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T.

Ther Apher Dial. 2008 Feb;12(1):42-8. doi: 10.1111/j.1744-9987.2007.00539.x.

PMID:
18257811
18.

Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.

Wazny LD, Raymond CB, Lesperance EM, Bernstein KN.

CANNT J. 2008 Apr-Jun;18(2):36-41, 44-50; quiz 42-3, 51-2. English, French.

PMID:
18669010
19.

Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.

Nephrol Dial Transplant. 2007 Apr;22(4):1171-6. Epub 2007 Jan 5.

20.

Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.

Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A.

Iran J Kidney Dis. 2007 Jul;1(1):25-8.

Items per page

Supplemental Content

Write to the Help Desk